Kornimate/medical-research-clean huggingface dataset:
comparison of sacral nerve modulation and pudendal nerve stimulation in treatment of fecal incontinence

Conditions: Fecal Incontinence

Summary: sacral nerve modulation (snm) is an established treatment for refractory lower urinary tract and bowel dysfunction (spinelli 2008). pudendal nerve stimulation (pns) has been proposed for patients failing snm treatment of urinary dysfunction (spinelli 2005). in this study snm and pns are compared for the treatment of fecal incontinence. in a test phase, both treatments will be applied for one week each in a randomized and blinded order (cross-over design). after the test phase the more successful treatment will be determined and applied permanently. if both treatments are equally sufficient, pns will be chosen for permanent stimulation, since preliminary data indicate that pns has a lower power consumption than snm. lower power consumption results in a longer lifetime of the stimulator, thus requiring less replacement surgeries.

primary surgery: * implantation of two electrodes, one placed next to the sacral nerve, one close to the pudendal nerve. electrode wires are passed through the skin just above the gluteal region and are marked s and p. one of the sub-investigators (not involved in the follow-up) replaces the s and p marks by 1 and 2 marks in absence of the operating surgeon. assignment of 1 and 2 is carried out in a predefined randomized fashion (computerized block randomization). test phase: * electrode labeled 1 is connected to a stimulator and the nerve is stimulated for one week, then the other electrode is stimulated for a week. * based on bowel habit diary, wexner score (jorge 1993) and subjective experience of the patient, the more successful treatment is chosen. if both electrodes were equally successful, the pudendal nerve electrode will be chosen for permanent stimulation. secondary surgery: * after unblinding, the less effective electrode is removed and the remaining electrode is connected to an implanted stimulator (permanent phase). in case both treatments were unsuccessful, both electrodes are removed.

Eligibility criteria:
inclusion criteria: * fecal incontinence nonresponsive to conservative treatment exclusion criteria: * sacral or perineal infection * sphincter defect larger than 60° (sonography) * pregnancy

Keywords: fecal incontinence colorectal surgery sacral nerve stimulation pudendal nerve stimulation
gabapentin treatment of alcohol dependence

Conditions: Alcoholism; Alcohol Dependence

Summary: gabapentin treatment for alcohol dependence

this is a 12-week, double blind, placebo controlled, dose ranging study to evaluate the efficacy of gabapentin in treating outpatients with alcohol dependence. subjects receive 900mg or 1800mg gabapentin or placebo daily for 12 weeks accompanied by weekly standardized counseling for alcohol-related behavior, with assessments of alcohol consumption, mood, sleep and alcohol-craving performed each week.

Eligibility criteria:
inclusion criteria: * men and women over age 18 with alcohol dependence exclusion criteria: * currently meets diagnostic and statistical manual 4 text revision (dsm-iv-tr) criteria for dependence on illicit substances * significant medical disorders that will increase potential risk or interfere with study participation * women with childbearing potential who are pregnant, nursing, or refuse to use a reliable method of birth control * treatment with an investigational drug in the last month.

Keywords: alcohol alcohol treatment alcoholism alcohol dependence
novel approach with double agent artificial oocyte activation for repeated fertilization failure due to combined sperm and oocyte factor

Conditions: Infertility

Summary: novel approach for oocyte fertilization failure for difficult cases not respond to traditional methods of assisted reproduction as intracytoplasmic sperm injection.

in some cases undergoes assisted reproduction technique specially intracytoplasmic sperm injection, in subgroup of patient they fail to fertilize or poorly fertilized, some authors recommend chemical activation for those group of patient with ca ionophore but still with ca ionophore there are some cases with total fertilization failure or low fertilization specially in those patient with 2 separate factors like teratozoospermia with poor quality oocytes so the investigators decided to test the effect of double activation methods by using tow agents proven with life birth rate ca ionophore and strontium chloride. we do intracytoplasmic sperm injection and immediately activate oocyte with ca ionophore followed by strontium chloride activation and monitoring the embryogenesis until the blastocyst formation and pregnancy outcome in multicenter assessment.

Eligibility criteria:
inclusion criteria: * poor sperm * poor quality oocytes * previous failed fertilization * previous poor embryogenesis exclusion criteria: * normal patient * previous successful outcome
role of serum total antioxidant level in preterm labor

Conditions: Preterm Labor

Summary: the aim of this study is to detect the association between maternal serum antioxidant level and preterm labor.

study design: this is a prospective case-control study. setting: the study will be conducted at ain shams university maternity hospital. population of the study: a total of 70 pregnant women attending the outpatient obstetric clinic and inpatient of obstetrics and gynecology department or when they will be admitted to the delivary room of ain shams university hospital. patient will be divided in to two groups. group a: 35 pregnant women diagnosed with preterm labor(preterm labor pain at least 3 contraction every 20 minutes ,cervical dilatation \< 2cm and effacement\< 50%) which will deliver within one week maximum after hospitalization. group b: 35 pregnant women( controls )with uncomplicated pregnancies at a similar gestational ages followed routinely in the antenatal care unit. every case will be subjected to:- 1. written informed consent before the study. 2. complete history . 3. complete general and abdominal examination. 4. infection markers(crp,wbcs count, urine analysis ). 5. gestational age determination by the last menstrual date or ultrasonography. 6. local pelvic examination.

Eligibility criteria:
inclusion criteria: * preterm labor(pregnant between 28th and 37th week). * singleton pregnancy. * amnion membranes were intact exclusion criteria: * past history of preterm labor or premature delivery. * urinary tract infections and any other infections. * poly- or oligohydramnios. * fetal distress, fetal or uterine anomaly. * membranes rupture and placenta pathology. * preeclampsia or intrauterine growth retardation

Keywords: antioxidant preterm labor
a phase 1 study in patients with solid tumors

Conditions: Solid Tumors

Summary: the primary objective of this study is to determine the maximum tolerated dose (mtd) regimen for the combination therapy of ly573636 and pemetrexed that may be safely administered to patients with a solid tumor that is not amenable to curative therapy.


Eligibility criteria:
inclusion criteria: * you must have a diagnosis of a solid tumor malignancy that is not amenable to curative therapy * you must have a serum albumin level greater than or equal to 3.0 grams per deciliter (g/dl) \[30 grams per liter (g/l)\] * you must have a performance status of 0 or 1 on the eastern cooperative oncology group (ecog) scale * you must be reliable and willing to make yourself available for the duration of the study and are willing to follow study procedures * patients with reproductive potential should use medically approved contraceptive precautions during the trial and for 6 months following the last dose of study drugs * your test results assessing the function of your blood, kidneys, liver, and heart are satisfactory * you must be willing to take folic acid, vitamin b12, or prophylactic steroids * you must able to interrupt the use of aspirin (other than an aspirin dose less than or equal to 1.3 grams per day) and/or other nonsteroidal anti-inflammatory agents for 2 days before, the day of, and 2 days after the dose of pemetrexed (5 days prior for long-acting agents, such as piroxicam) * you must have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, immunotherapy, hormone therapy, or other investigational therapy for at least 4 weeks (6 weeks for mitomycin-c or nitrosoureas) before study enrollment and recovered from the acute effects of therapy (except alopecia). patients who have received whole-brain radiation must wait 90 days before starting study therapy. * you must sign an informed consent exclusion criteria: * you cannot have received other investigational drugs within the last 30 days * you cannot have other on-going serious illnesses including active bacterial, fugal, or viral infections * you cannot require regular, periodic paracentesis or thoracentesis * you cannot have active brain metastasis * you cannot currently be receiving warfarin (coumadin®) therapy * you cannot be pregnant or lactating * you cannot have received prior pemetrexed or ly573636 * you cannot have a second primary malignancy that could affect interpretation of the study results

Keywords: solid tumors
study in end-stage renal disease patients awaiting kidney transplant to investigate the potential effect of ivig treatment on the pharmacokinetics and pharmacodynamics of lfg316

Conditions: Kidney Transplantation

Summary: investigate whether concomitant treatment with intravenous immunoglobulin (ivig) can alter the pharmacokinetics and pharmacodynamics of lfg316 to an extent which would necessitate dose adaptation for lfg316 in pre-sensitized end-stage renal disease patients awaiting kidney transplantation


Eligibility criteria:
inclusion criteria: 1. adult men or women 18-70 years of age suffering from end-stage renal disease and who are on chronic dialysis therapy. 2. candidates for kidney transplantation who are pre-sensitized and will be undergoing desensitization therapy. 3. written informed consent must be obtained before any assessment is performed. 4. able to communicate well with the investigator, to understand and comply with the requirements of the study. 5. recipients who are abo compatible with donor allograft. 6. patients awaiting kidney allograft from a living or deceased donor. for patients awaiting transplant from a living donor, kidney transplantation must only occur after 28 days post-lfg316 infusion. 7. history of vaccination with meningococcus and pneumococcus between 2 weeks and 36 months prior to dosing. documentation is required. if patients have not been vaccinated, they must be vaccinated at least 2 weeks prior to dosing. the choice of vaccine(s) should take into account the serotypes prevalent in the geographic areas in which study patients will be enrolled. exclusion criteria: 1. patients requiring or undergoing peritoneal dialysis. 2. patients with a known contraindication to treatment with blood products. 3. patients with a known pro-thrombotic disorder and/or history of thrombosis or hyper-coagulable state, excluding hemodialysis venous access clotting. 4. patients who have positive pcr results for hepatitis b and/or hepatitis c, and/or history of immunodeficiency diseases, including a positive hiv (elisa and western blot) test result. 5. patients at risk for tuberculosis (tb) 6. patients with any severe, progressive or uncontrolled acute or chronic medical condition not related to end-stage renal disease (such as uncontrolled infectious disease or sepsis), clinical laboratory abnormalities at screening or baseline that in the investigator's opinion would make the patient inappropriate for entry into this study, or known active presence of malignancies. 7. pregnant or nursing (lactating) women. 8. women of child-bearing potential, unless highly effective methods of contraception are used during dosing and for 50 days after the last dose of lfg316, or sexually active males unwilling to use a condom during intercourse while taking investigational drug and for 50 days after the last dose of lfg316. other protocol-defined inclusion/exclusion criteria may apply.
smartphone intervention for subthreshold depression

Conditions: Subthreshold Depression

Summary: the study aimed to examine the feasibility, usability, user satisfaction, safety, and preliminary efficacy of a smartphone application intervention for young adults with subthreshold depression.


Eligibility criteria:
inclusion criteria: * aged 18-24 years * has a center for epidemiologic studies depression scale score of ≥16 * owns a smartphone with the ios® operating system exclusion criteria: * lifetime history of major depressive disorder * lifetime history of bipolar disorder * currently receiving treatment for a mental health problem from a mental health professional * experience of a major depressive episode in the 2 weeks prior to the study, as ascertained using the mini-international neuropsychiatric interview
effect of dietary fiber intervention on patients with polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: the purpose of the study is to understand the effect of dietary fiber on patients with polycystic ovary syndrome.


Eligibility criteria:
inclusion criteria: 1. individuals who are 20 to 40 years old, planning to become pregnant or infertile women. 2. individuals who are diagnosed as pcos according to rotterdam pcos diagnostic criteria: 1）oligomenorrhea or amenorrhea or irregular uterine bleeding 2) hyperandrogenism or hyperandrogenism; 3) ultrasonography showing polycystic ovary, while excluding other diseases that may cause hyperandrogenism and ovulation abnormalities. meets at least two of the three criterias. 3. individuals who can insist on continuous monitoring in the outpatient clinic, 4. individuals who are not participating in other research projects currently or 3 months before the intervention. exclusion criteria: 1. individuals who suffering from other diseases that may cause hyperandrogenism and ovulation abnormalities. 2. individuals who are during pregnant, lactation or menopause. 3. individuals who currently receiving weight-loss drugs or surgery or within the past 2 months. 4. individuals who suffer from infectious diseases such as hepatitis b, active tuberculosis, aids, etc. 5. individuals who need regular medication to treat chronic diseases such as diabetes, hypertension, gout, hyperuricemia, etc. 6. use of medications that affect hormone levels, appetite, carbohydrate absorption, and metabolism within the past 2 months. 7. individuals with severe liver diseases or kidney disease that are ineligible to participate in the study. 8. a medical history of severe cardiovascular and cerebrovascular diseases. 9. individuals who currently suffer from severe gastrointestinal diseases or undergo gastrointestinal resection that may affect nutrient absorption. 10. individuals who drink more than 15g of alcohol per day or have a smoking habit. 11. individuals who need drug treatment for any mental illness such as epilepsy and depression. 12. cancer patients.
impact of surgical mask, ffp2 mask and ffp3 mask (with and without exhalation valve) on exercise tolerance and blood gas parameters of patients with known lung disease and long-term oxygen therapy

Conditions: Face Mask; Longterm Oxygen Therapy

Summary: the aim of the study is to find out how blood gas parameters change under the use of surgical mask, ffp2 masks and ffp3 masks (with and without exhalation valve) in patients with known lung disease and long-term oxygen therapy. in particular, the question arises whether patients become hypoxemic or hypercapnic by using a mask. or whether wearing a mask increases oxygen saturation by its reservoir function.


Eligibility criteria:
inclusion criteria: * known lung disease and * ltot * informed consent exclusion criteria: * severe disease with contraindication for stress testing (e.g. myocardial infarction, acute pulmonary embolism, acute heart failure) * acute exacerbation of lung disease
new treatment of alopecia areata

Conditions: Alopecia Areata

Summary: abstract: alopecia areata is believed to be an autoimmune disease resulting from a breach in the immune privilege of the hair follicles causing non scarring hair loss. methods: our study included 40 patients from may 2019 to july 2022 diagnosed clinically, dermatoscopically and pathologically as alopecia areata data were enrolled from department of dermatology and venereology, al-hussein hospital.

for each patient the following will be done : 1. history taking including ( age, sex, disease duration, family history, history of drug intake, smoking and history of any associated disease ). 2. all patients will give a written, informed consent for induction. 3. basic photographs will be taken to assess site, size (by cm), number, extent of the patch using d5300 camera with lens (18-55). 4. patients will be subjected to 3 session of trichloroacetic acid (tca) 35% one month apart. 5. serial photographs and dermoscopic examination every month will be done and patient will be score. 6. efficacy will be assessed using prognostic scoring system for density, pigmentation, and texture of growing hair. 7. histopathological examination will be done before the first session and one month after third session.

Eligibility criteria:
inclusion criteria: * alopecia areata multilocularis and alopecia totalis. age from 16-60 years old. ophiasis pattern alopecia areata. exclusion criteria: * age less than 16 and more than 60years old. alopecia areata of the face. * patient under treatment.

Keywords: alopecia areata aa
a study evaluating efruxifermin in subjects with non-cirrhotic nonalcoholic steatohepatitis (nash)/metabolic dysfunction-associated steatohepatitis (mash) and fibrosis

Conditions: NASH With Fibrosis; MASH With Fibrosis

Summary: this is a multi-center evaluation of efruxifermin (efx) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic nash/mash and fibrosis stage 2 or 3 (f2 or f3). the study will enroll subjects in two cohorts for a total samples size of 1650 subjects.


Eligibility criteria:
inclusion criteria: * males and non-pregnant, non-lactating females between 18 - 80 years of age inclusive, based on the date of the screening visit. * previous history or presence of 2 out of 4 components of metabolic syndrome (obesity, dyslipidemia, elevated blood pressure, elevated fasting glucose) or type 2 diabetes. * cohort 1: biopsy-proven nash/mash. must have had a liver biopsy obtained ≤ 180 days prior to screening with fibrosis stage 2 or 3 and a non-alcoholic fatty liver disease (nafld) activity score (nas) of ≥ 4 with at least a score of 1 in each of the following nas components: * steatosis (scored 0 to 3), * ballooning degeneration (scored 0 to 2), and * lobular inflammation (scored 0 to 3). exclusion criteria: * other causes of liver disease based on medical history and/or liver histology and/or central laboratory results. * presence of cirrhosis on liver biopsy (fibrosis stage 4). * type 1 or uncontrolled type 2 diabetes. other inclusion and exclusion criteria may apply.
home-based brain stimulation treatment for post-acute sequelae of covid-19 (pasc)

Conditions: Dysexecutive Syndrome; Post-Acute Sequelae of COVID-19

Summary: the main goal of this study is to improve dysexecutive symptoms (e.g., sustained attention, processing speed) in patients exhibiting post-acute sequelae of covid-19 (pasc) through home-based transcranial direct current stimulation (tdcs), a noninvasive method that uses low intensity electric currents delivered to the brain through stimulation electrodes on the scalp.


Eligibility criteria:
inclusion criteria: * ability to provide informed consent * a diagnosis of pasc as indicated by past covid-19 infection, and persistent symptoms, including 'brain fog', confusion, short-term memory deficits, trouble concentrating, delirium, difficulties in multitasking. exclusion criteria: * history of epilepsy * metallic implants in the head and neck, * brain stimulators * pacemakers * pregnancy * active substance dependence (except for tobacco) * premorbid major neurological illness * severe mental illness (e.g., bipolar disorder, schizophrenia) * attention deficit hyperactivity disorder

Keywords: transcranial direct current stimulation eeg sustained attention
outpatient nurse monitoring under the prevention of recurrent suicidal

Conditions: Mood Disorder; Reactive Depression

Summary: to evaluate the impact of a specific nursing management (personalized and close, through consultation at the hospital, at home or by phone) monitoring in post-hospitalization, the suicide attempt of recurrence and suicidal crisis, in the year following a suicide attempt in patients suffering from a mood disorder (unipolar or bipolar) or reactive depression.

main objective: to evaluate the impact of a specific nursing management (personalized and close, through consultation at the hospital, at home or by phone) monitoring in post-hospitalization, the suicide attempt of recurrence and suicidal crisis, in the year following a suicide attempt in patients suffering from a mood disorder (unipolar or bipolar) or reactive depression. secondary objectives: studying during the year following the suicide attempt index, the impact of this device on: * the frequency and intensity of suicidal ideation * the spontaneous use of emergency care * the death rate from suicide and other causes * the cumulative duration of hospitalization for suicidal behavior * the patient's quality of life * the number of patients lost to at the end of search studying patient compliance with intensive nursing monitoring program. to study the role of the nurse to determine the factors that promote the construction of a therapeutic alliance. establish a mapping of needs and resources suicidal patient for nursing care in post-emergency.

Eligibility criteria:
inclusion criteria: * patient suffering from a mood disorder (unipolar or bipolar) or reactive depression whose reason for hospitalization in the psychiatric emergency unit post has attempted suicide exclusion criteria: * patients with bipolar disorder, current episode manic in * patient hospitalized full-time (for high suicide risk incompatible with an output of emergencies or clinical transfer) within 3-5 days of the ts * patient suffering from a somatic pathology associated with the prognosis is committed in the short term. * patients suffering from a neurodegenerative pathology of dementia or pre-dementia types. * homeless patient
comparing the efficacy of nitazoxanide versus rifaximin in adult patients with irritable bowel syndrome without constipation

Conditions: Irritable Bowel Syndrome With Diarrhea

Summary: this study aim to compare the efficacy of nitazoxanide in 2-week course of treatment with rifaximin in treating diarrhea associated with ibs. we also aim to study its effect over 10 weeks after treatment to evaluate its efficacy in eradicating symptoms of ibs in the long run.


Eligibility criteria:
inclusion criteria: * patients 18 years of age or older. * patients suffering from diarrhea-predominant ibs according to rome iii criteria. * active symptoms for at least 2 weeks * abdominal pain intensity: weekly average of worst daily (in past 24 hours) abdominal pain score of \> 3.0 on a 0-to-10-point scale and stool consistency: at least one stool with a consistency of type 6 or type 7 bristol stool score (bss) on at least 2 days per week * report no restriction whatsoever on their diet. exclusion criteria: * presence of liver disease, malignancy, severe malabsorption, bedridden, endocrinological disorders, or severe chronic obstructive pulmonary disease. * patients who have undergone abdominal surgeries except for appendectomy and/or cholecystectomy and/or hysterectomy. * patients who consumed any medications that may affect bowel function within the last 2 weeks such as antibiotics, probiotics, prebiotics, antispasmodics, antidiarrheals, narcotics, or any other medication that may alter bowel function * patients on antidepressants or antipsychotics starting within the last six weeks before eligibility check.